Stoke Therapeutics Company Description

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.

The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels.

Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials.

The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye.

It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases.

The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016.

Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Stoke Therapeutics, Inc.

Country	United States
Founded	2014
Industry	Biological Products, Except Diagnostic Substances
Employees	128
CEO	Ian Smith

Contact Details

Address: 45 Wiggins Avenue Bedford, Delaware 01730 United States
Phone	781 430 8200
Website	stoketherapeutics.com

Stock Details

Ticker Symbol	0GT
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Ian Smith	Chief Executive Officer
Thomas Edward Leggett	Chief Financial Officer
Doug Snow	Head of Investor Relations